Cancer BiologybioRxiv
Tumor suppressor PLK2 may serve as a biomarker in triple-negative breast cancer for improved response to PLK1 therapeutics
Y. Gao, E. B. Kabotyanski, E. Villegas…·J. M. Rosen
This study shows PLK2 loss predicts better response to PLK1 inhibitors in triple-negative breast cancer and suggests PLK2 as a biomarker for treatment response.
DOI 10.1158/2767-9764.crc-21-0106